Cimetidine as an adjuvant treatment in colorectal cancer : a double-blind, randomized pilot study
To evaluate the influence of a H2 receptor antagonist (cimetidine) on survival in patients with colorectal carcinoma, a randomized, controlled pilot study was performed in three university hospitals in Copenhagen, Denmark. A total of 192 patients, who had undergone a resection or an exploratory oper...
Gespeichert in:
| Veröffentlicht in: | Diseases of the colon & rectum 1995-05, Vol.38 (5), p.514-518 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 518 |
|---|---|
| container_issue | 5 |
| container_start_page | 514 |
| container_title | Diseases of the colon & rectum |
| container_volume | 38 |
| creator | SVENDSEN, L. B ROSS, C KNIGGE, U FREDERIKSEN, H. J GRAVERSEN, P KJAERGARD, J LUKE, M STIMPEL, H SPARSØ, B. H |
| description | To evaluate the influence of a H2 receptor antagonist (cimetidine) on survival in patients with colorectal carcinoma, a randomized, controlled pilot study was performed in three university hospitals in Copenhagen, Denmark.
A total of 192 patients, who had undergone a resection or an exploratory operation for adenocarcinoma of the colon or rectum between May 1988 and May 1991, were enrolled in the study. After a median observation time of 40 months, outcome was noted for each patient concerning cancer-specific mortality rate.
In patients operated with curative intent (n = 148), no difference was found in cancer-specific mortality between the two treatments. However, a tendency toward reduction in mortality rate was found in patients with curatively operated Dukes Stage C carcinoma (P = 0.11, log-rank test; difference, 29 percent; 90 percent confidence interval, 2 to 57 percent) in the cimetidine-treated group. In patients with disseminated disease no total difference was found between the two treatment groups.
Cimetidine does not seem to reduce mortality in patients with colorectal cancer, but there seems to be a tendency toward a survival benefit in patients undergoing surgery for Dukes Stage C carcinoma. Results seem to justify trials in this patient category to reveal a benefit of H2 receptor antagonists in adjuvant therapy of colorectal carcinoma. |
| doi_str_mv | 10.1007/BF02148852 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77243700</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77243700</sourcerecordid><originalsourceid>FETCH-LOGICAL-c270t-b0d23bfc972d5bec3be83e1baa19b89f2d8320aeee55744c9d8b77956cacedde3</originalsourceid><addsrcrecordid>eNpFkEtLxDAUhYMoOj427oUsxIVYTZNmkrrTwRcIbnRdbpJbyJC2Y5IK46-3MoOu7rmcj7P4CDkt2XXJmLq5f2S8rLSWfIfMSilYwYTUu2TGWMkLodj8gBymtJxexpnaJ_tKibnWYkZg4TvM3vkeKSQKPQW3HL-gzzRHhNzhlHxP7RCGiDZDoBZ6i5HeUqBuGE3AwgTfuysaoXdD57_R0ZUPQ6Ypj259TPZaCAlPtveIfDw-vC-ei9e3p5fF3WthuWK5MMxxYVpbK-6kQSsMaoGlAShro-uWOy04A0SUUlWVrZ02StVybsGicyiOyMVmdxWHzxFTbjqfLIYAPQ5japTi1aSCTeDlBrRxSCli26yi7yCum5I1vz6bf58TfLZdHU2H7g_dCpz6820PyUJoJwfWpz9MSM4lr8UPped90A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77243700</pqid></control><display><type>article</type><title>Cimetidine as an adjuvant treatment in colorectal cancer : a double-blind, randomized pilot study</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><source>Journals@Ovid Complete</source><creator>SVENDSEN, L. B ; ROSS, C ; KNIGGE, U ; FREDERIKSEN, H. J ; GRAVERSEN, P ; KJAERGARD, J ; LUKE, M ; STIMPEL, H ; SPARSØ, B. H</creator><creatorcontrib>SVENDSEN, L. B ; ROSS, C ; KNIGGE, U ; FREDERIKSEN, H. J ; GRAVERSEN, P ; KJAERGARD, J ; LUKE, M ; STIMPEL, H ; SPARSØ, B. H</creatorcontrib><description>To evaluate the influence of a H2 receptor antagonist (cimetidine) on survival in patients with colorectal carcinoma, a randomized, controlled pilot study was performed in three university hospitals in Copenhagen, Denmark.
A total of 192 patients, who had undergone a resection or an exploratory operation for adenocarcinoma of the colon or rectum between May 1988 and May 1991, were enrolled in the study. After a median observation time of 40 months, outcome was noted for each patient concerning cancer-specific mortality rate.
In patients operated with curative intent (n = 148), no difference was found in cancer-specific mortality between the two treatments. However, a tendency toward reduction in mortality rate was found in patients with curatively operated Dukes Stage C carcinoma (P = 0.11, log-rank test; difference, 29 percent; 90 percent confidence interval, 2 to 57 percent) in the cimetidine-treated group. In patients with disseminated disease no total difference was found between the two treatment groups.
Cimetidine does not seem to reduce mortality in patients with colorectal cancer, but there seems to be a tendency toward a survival benefit in patients undergoing surgery for Dukes Stage C carcinoma. Results seem to justify trials in this patient category to reveal a benefit of H2 receptor antagonists in adjuvant therapy of colorectal carcinoma.</description><identifier>ISSN: 0012-3706</identifier><identifier>EISSN: 1530-0358</identifier><identifier>DOI: 10.1007/BF02148852</identifier><identifier>PMID: 7736883</identifier><identifier>CODEN: DICRAG</identifier><language>eng</language><publisher>Secaucus, NJ: Springer</publisher><subject>Adenocarcinoma - drug therapy ; Adenocarcinoma - mortality ; Adenocarcinoma - surgery ; Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Chemotherapy, Adjuvant ; Cimetidine - therapeutic use ; Colonic Neoplasms - drug therapy ; Colonic Neoplasms - mortality ; Colonic Neoplasms - surgery ; Denmark - epidemiology ; Digestive system ; Double-Blind Method ; Female ; Follow-Up Studies ; Humans ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Pilot Projects ; Placebos ; Rectal Neoplasms - drug therapy ; Rectal Neoplasms - mortality ; Rectal Neoplasms - surgery ; Survival Rate ; Treatment Outcome</subject><ispartof>Diseases of the colon & rectum, 1995-05, Vol.38 (5), p.514-518</ispartof><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c270t-b0d23bfc972d5bec3be83e1baa19b89f2d8320aeee55744c9d8b77956cacedde3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,776,780,785,786,23909,23910,25118,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3522529$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7736883$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SVENDSEN, L. B</creatorcontrib><creatorcontrib>ROSS, C</creatorcontrib><creatorcontrib>KNIGGE, U</creatorcontrib><creatorcontrib>FREDERIKSEN, H. J</creatorcontrib><creatorcontrib>GRAVERSEN, P</creatorcontrib><creatorcontrib>KJAERGARD, J</creatorcontrib><creatorcontrib>LUKE, M</creatorcontrib><creatorcontrib>STIMPEL, H</creatorcontrib><creatorcontrib>SPARSØ, B. H</creatorcontrib><title>Cimetidine as an adjuvant treatment in colorectal cancer : a double-blind, randomized pilot study</title><title>Diseases of the colon & rectum</title><addtitle>Dis Colon Rectum</addtitle><description>To evaluate the influence of a H2 receptor antagonist (cimetidine) on survival in patients with colorectal carcinoma, a randomized, controlled pilot study was performed in three university hospitals in Copenhagen, Denmark.
A total of 192 patients, who had undergone a resection or an exploratory operation for adenocarcinoma of the colon or rectum between May 1988 and May 1991, were enrolled in the study. After a median observation time of 40 months, outcome was noted for each patient concerning cancer-specific mortality rate.
In patients operated with curative intent (n = 148), no difference was found in cancer-specific mortality between the two treatments. However, a tendency toward reduction in mortality rate was found in patients with curatively operated Dukes Stage C carcinoma (P = 0.11, log-rank test; difference, 29 percent; 90 percent confidence interval, 2 to 57 percent) in the cimetidine-treated group. In patients with disseminated disease no total difference was found between the two treatment groups.
Cimetidine does not seem to reduce mortality in patients with colorectal cancer, but there seems to be a tendency toward a survival benefit in patients undergoing surgery for Dukes Stage C carcinoma. Results seem to justify trials in this patient category to reveal a benefit of H2 receptor antagonists in adjuvant therapy of colorectal carcinoma.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - surgery</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy, Adjuvant</subject><subject>Cimetidine - therapeutic use</subject><subject>Colonic Neoplasms - drug therapy</subject><subject>Colonic Neoplasms - mortality</subject><subject>Colonic Neoplasms - surgery</subject><subject>Denmark - epidemiology</subject><subject>Digestive system</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Pilot Projects</subject><subject>Placebos</subject><subject>Rectal Neoplasms - drug therapy</subject><subject>Rectal Neoplasms - mortality</subject><subject>Rectal Neoplasms - surgery</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><issn>0012-3706</issn><issn>1530-0358</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkEtLxDAUhYMoOj427oUsxIVYTZNmkrrTwRcIbnRdbpJbyJC2Y5IK46-3MoOu7rmcj7P4CDkt2XXJmLq5f2S8rLSWfIfMSilYwYTUu2TGWMkLodj8gBymtJxexpnaJ_tKibnWYkZg4TvM3vkeKSQKPQW3HL-gzzRHhNzhlHxP7RCGiDZDoBZ6i5HeUqBuGE3AwgTfuysaoXdD57_R0ZUPQ6Ypj259TPZaCAlPtveIfDw-vC-ei9e3p5fF3WthuWK5MMxxYVpbK-6kQSsMaoGlAShro-uWOy04A0SUUlWVrZ02StVybsGicyiOyMVmdxWHzxFTbjqfLIYAPQ5japTi1aSCTeDlBrRxSCli26yi7yCum5I1vz6bf58TfLZdHU2H7g_dCpz6820PyUJoJwfWpz9MSM4lr8UPped90A</recordid><startdate>19950501</startdate><enddate>19950501</enddate><creator>SVENDSEN, L. B</creator><creator>ROSS, C</creator><creator>KNIGGE, U</creator><creator>FREDERIKSEN, H. J</creator><creator>GRAVERSEN, P</creator><creator>KJAERGARD, J</creator><creator>LUKE, M</creator><creator>STIMPEL, H</creator><creator>SPARSØ, B. H</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19950501</creationdate><title>Cimetidine as an adjuvant treatment in colorectal cancer : a double-blind, randomized pilot study</title><author>SVENDSEN, L. B ; ROSS, C ; KNIGGE, U ; FREDERIKSEN, H. J ; GRAVERSEN, P ; KJAERGARD, J ; LUKE, M ; STIMPEL, H ; SPARSØ, B. H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c270t-b0d23bfc972d5bec3be83e1baa19b89f2d8320aeee55744c9d8b77956cacedde3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - surgery</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy, Adjuvant</topic><topic>Cimetidine - therapeutic use</topic><topic>Colonic Neoplasms - drug therapy</topic><topic>Colonic Neoplasms - mortality</topic><topic>Colonic Neoplasms - surgery</topic><topic>Denmark - epidemiology</topic><topic>Digestive system</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Pilot Projects</topic><topic>Placebos</topic><topic>Rectal Neoplasms - drug therapy</topic><topic>Rectal Neoplasms - mortality</topic><topic>Rectal Neoplasms - surgery</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SVENDSEN, L. B</creatorcontrib><creatorcontrib>ROSS, C</creatorcontrib><creatorcontrib>KNIGGE, U</creatorcontrib><creatorcontrib>FREDERIKSEN, H. J</creatorcontrib><creatorcontrib>GRAVERSEN, P</creatorcontrib><creatorcontrib>KJAERGARD, J</creatorcontrib><creatorcontrib>LUKE, M</creatorcontrib><creatorcontrib>STIMPEL, H</creatorcontrib><creatorcontrib>SPARSØ, B. H</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diseases of the colon & rectum</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SVENDSEN, L. B</au><au>ROSS, C</au><au>KNIGGE, U</au><au>FREDERIKSEN, H. J</au><au>GRAVERSEN, P</au><au>KJAERGARD, J</au><au>LUKE, M</au><au>STIMPEL, H</au><au>SPARSØ, B. H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cimetidine as an adjuvant treatment in colorectal cancer : a double-blind, randomized pilot study</atitle><jtitle>Diseases of the colon & rectum</jtitle><addtitle>Dis Colon Rectum</addtitle><date>1995-05-01</date><risdate>1995</risdate><volume>38</volume><issue>5</issue><spage>514</spage><epage>518</epage><pages>514-518</pages><issn>0012-3706</issn><eissn>1530-0358</eissn><coden>DICRAG</coden><abstract>To evaluate the influence of a H2 receptor antagonist (cimetidine) on survival in patients with colorectal carcinoma, a randomized, controlled pilot study was performed in three university hospitals in Copenhagen, Denmark.
A total of 192 patients, who had undergone a resection or an exploratory operation for adenocarcinoma of the colon or rectum between May 1988 and May 1991, were enrolled in the study. After a median observation time of 40 months, outcome was noted for each patient concerning cancer-specific mortality rate.
In patients operated with curative intent (n = 148), no difference was found in cancer-specific mortality between the two treatments. However, a tendency toward reduction in mortality rate was found in patients with curatively operated Dukes Stage C carcinoma (P = 0.11, log-rank test; difference, 29 percent; 90 percent confidence interval, 2 to 57 percent) in the cimetidine-treated group. In patients with disseminated disease no total difference was found between the two treatment groups.
Cimetidine does not seem to reduce mortality in patients with colorectal cancer, but there seems to be a tendency toward a survival benefit in patients undergoing surgery for Dukes Stage C carcinoma. Results seem to justify trials in this patient category to reveal a benefit of H2 receptor antagonists in adjuvant therapy of colorectal carcinoma.</abstract><cop>Secaucus, NJ</cop><pub>Springer</pub><pmid>7736883</pmid><doi>10.1007/BF02148852</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-3706 |
| ispartof | Diseases of the colon & rectum, 1995-05, Vol.38 (5), p.514-518 |
| issn | 0012-3706 1530-0358 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77243700 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings; Journals@Ovid Complete |
| subjects | Adenocarcinoma - drug therapy Adenocarcinoma - mortality Adenocarcinoma - surgery Adult Aged Aged, 80 and over Biological and medical sciences Chemotherapy, Adjuvant Cimetidine - therapeutic use Colonic Neoplasms - drug therapy Colonic Neoplasms - mortality Colonic Neoplasms - surgery Denmark - epidemiology Digestive system Double-Blind Method Female Follow-Up Studies Humans Male Medical sciences Middle Aged Pharmacology. Drug treatments Pilot Projects Placebos Rectal Neoplasms - drug therapy Rectal Neoplasms - mortality Rectal Neoplasms - surgery Survival Rate Treatment Outcome |
| title | Cimetidine as an adjuvant treatment in colorectal cancer : a double-blind, randomized pilot study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T18%3A36%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cimetidine%20as%20an%20adjuvant%20treatment%20in%20colorectal%20cancer%20:%20a%20double-blind,%20randomized%20pilot%20study&rft.jtitle=Diseases%20of%20the%20colon%20&%20rectum&rft.au=SVENDSEN,%20L.%20B&rft.date=1995-05-01&rft.volume=38&rft.issue=5&rft.spage=514&rft.epage=518&rft.pages=514-518&rft.issn=0012-3706&rft.eissn=1530-0358&rft.coden=DICRAG&rft_id=info:doi/10.1007/BF02148852&rft_dat=%3Cproquest_cross%3E77243700%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77243700&rft_id=info:pmid/7736883&rfr_iscdi=true |